FTSE 100 movers: Miners weigh heavily after Chinese data disappoints
30th Sep 2013 14:19
Mining stocks declining sharply today on the back of the disappointing data from the world's top metals user, China. Fresnillo, Anglo American, Antofagasta, Glencore Xstrata and Rio Tinto were all falling sharply. China´s manufacturing sector purchasing managers´ index (PMI) for the month of Septe
Read moreLondon midday: Miners drag FTSE 100 to one-month low
30th Sep 2013 11:42
Concerns over a potential government shutdown in the US, political chaos in Italy and disappointing economic figures from China sparked steep falls on equity markets across Europe on Monday morning, with the FTSE 100 slipping to levels not seen in a month. The FTSE 100 was trading around 0.85% lowe
Read moreAstraZeneca delivers good news on Naloxegol
27th Sep 2013 07:31
Pharmaceutical giant AstraZeneca said the European Medicines Agency had accepted the marketing authorisation application for its constipation tablet Naloxegol. The investigational drug is aimed at relieving constipation caused by pain-killing opioid medicines. It was developed using technology from
Read moreLondon close: Stocks hit by Bullard comments as post-Fed rally fades
20th Sep 2013 16:39
The exuberant post-Fed mood quickly faded on Friday with comments from one US policymaker dampening stocks before the close of trade. Risk appetite was also scaled back as caution set in ahead of the German elections at the weekend with the outcome still highly uncertain. The FTSE 100 finished 28.
Read moreAstraZeneca flu vaccine wins backing from EU regulators
20th Sep 2013 15:08
Pharmaceuticals group AstraZeneca has received a green light from European regulators for its nasal influenza vaccine, giving its share price a small boost on Friday. The company said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a "posit
Read moreBroker tips: AstraZeneca, Pennon, Wetherspoon
13th Sep 2013 12:57
Jefferies has slashed its price target for pharmaceuticals group AstraZeneca (AZN) from 3,200p to 2,850p on the back of its concerns about the company's position in the respiratory market. The broker, which maintained its 'hold' rating for the stock, said that AZN's respiratory portfolio "does not
Read moreBroker snap: Jefferies cuts AstraZeneca target on respiratory concerns
13th Sep 2013 12:25
Jefferies has slashed its price target for pharmaceuticals group AstraZeneca (AZN) from 3,200p to 2,850p on the back of its concerns about the company's position in the respiratory market. The broker, which maintained its 'hold' rating for the stock, said that AZN's respiratory portfolio "does not
Read moreFriday broker round-up UPDATE
13th Sep 2013 08:26
ASOS: Panmure Gordon raises target price from 4555p to 5950p maintaining a buy recommendation. AstraZeneca: Jefferies reduces target price from 3200p to 2850p and retains a hold recommendation. Barclays: Jefferies initiates with a target price of 367p and a buy recommendation. Barratt Development
Read moreTuesday broker round-up UPDATE
10th Sep 2013 08:17
African Barrick Gold: Investec shifts target price from 135p to 137p, while downgrading from hold to sell. Aquarius Platinum: JP Morgan moves target price from 39p to 49p, while downgrading from neutral to underweight. Citi lowers target price from 66p to 54p and downgrades from buy to neutral. As
Read moreAstraZeneca launches phase III programme for olaparib
4th Sep 2013 07:22
AstraZeneca has started a phase III clinical programme for olaparib, a potential treatment for ovarian cancer. The pharma giant said it had enrolled its first patient for the programme, which is being conducted with the Gynecologic Oncology Group and the SOLO 2 study with the European Network of Gy
Read moreWednesday broker round-up
28th Aug 2013 08:09
African Barrick Gold: Nomura takes target price from 155p to 250p and reiterates its buy recommendation. Antofagasta: Deutsche Bank cuts target price from 1050p to 1035p and retains a hold recommendation. JP Morgan reduces target price from 1005p to 975p, while its neutral rating remains unchanged.
Read moreAstraZeneca acquires US biologics firm
27th Aug 2013 07:21
AstraZeneca announced Tuesday that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology. The acquisition will be made
Read moreTuesday newspaper round-up: Saudi Arabia, Russian, Services
27th Aug 2013 07:00
Saudi Arabia has secretly offered Russia a sweeping deal to control the global oil market and safeguard Russia's gas contracts, if the Kremlin backs away from the Assad regime in Syria. The revelations come amid high tension in the Middle East, with US, British, and French warship poised for missile
Read moreLondon open: Stocks fall as markets await Carney's forward guidance
7th Aug 2013 08:31
Markets opened with moderate losses on Wednesday morning as investors turned nervous ahead of the Bank of England's inflation report, the first under the governorship of Mark Carney. The heavyweight mining sector was again providing a drag on the FTSE 100 as metals prices fell, while a number of b
Read moreLondon close: Markets surge on upbeat data, policy decisions
1st Aug 2013 16:43
Markets rose strongly on Thursday as investors reacted to dovish comments from central banks across the globe, upbeat economic data and well-received results from UK banking group Lloyds. The FTSE 100 finished 61 points higher at 6,682 today, rising to levels not seen since the end of May. "The th
Read more